Development and pre-clinical assessment of a first-in-class small molecule inhibitor of FLIP for treatment of NSCLC and CRC
Catherine Higgins(Queen's University Belfast), Daniel B. Longley(Queen's University Belfast), Joanna Majkut(Queen's University Belfast), Adnan Malik(European Bioinformatics Institute), Zsusannah Nemeth, Peter Blurton, Trevor R. Perrior, Margarita Espona‐Fiedler(Umeå University), Ray Boffey, J.S. Fox, T. Harrison, David Haigh, Luke Humphreys(Queen's University Belfast)
Cited by 2
Related Papers
MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma
|Modern Pathology|2014|174
Synthetic Prodiginine Obatoclax (GX15‐070) and Related Analogues: Anion Binding, Transmembrane Transport, and Cytotoxicity Properties
|Chemistry - A European Journal|2011|116
<scp>FLIP</scp> as a therapeutic target in cancer
|FEBS Journal|2018|86
Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: Prodigiosin vs. obatoclax
|Biochemical Pharmacology|2011|74
Down-Regulation of miR-29b Is Essential for Pathogenesis of Uterine Leiomyoma
|Endocrinology|2014|73